HIGETA SHOYU
Animal Origin-Free / GMP-compliant grade

Recombinant Human EGF
From recombinant Brevibacillus choshinensis 1)
100 ㎍
500 ㎍
10 mg

Order no. REG100UG
Order no. REG500UG
Order no. REG10MG

1. Description
Epidermal growth factor (EGF), discovered in 1979, has
growth promoting effect on a wide range of epithelial andepidermal cells including fibroblasts, glial cells, mammary
epithelial cells, vascular and corneal endothelial cells,
2)bovine granulosa, Hela cells, and SV-40-3T3 cells . EGF
has been used in many trials in a medical field and reported
to be effective on the proliferation of human epidermal cells4)
and corneal endothelial cells (regenerative medicine),
regeneration of liver, and healing of gastroduodenal ulcers.
In veterinary medicine too, EGF has many applications. For
example, it has been demonstrated that the cataplasm5)
containing EGF had wound healing effect . Furthermore,
EGF has currently been used as a component of cell culture
media.

2. Properties
Molecular Weight : 6217.55 (TOF-MS)
3)
Isoelectric point : ca. 4.5
AA sequence :NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELR

3. Source
A DNA sequence encoding the mature human EGF
protein was expressed in Brevibacillus choshinensis.
4. Specification
TEST

SPECIFICATION

Appearance

White powder

Visual inspection

BiologicalActivity＜0.2 ng / ml (ED50)

Cell Proliferation
ELISA*Purity 1＞95%

RP-HPLC

Purity 2＞98%

SDS-PAGE

Endotoxin＜0.01 EU /㎍ EGF

LAL assay

Negative

Plate-count Method

Microbial Limit
Test

METHOD*Measured by its ability to stimulate 5-bromo-2'-deoxyuridine incorporation
into an EGF-responsive mouse fibroblast cell line, Balb/c3T3.

Stabilizer

Not containedSizes
Package
Storage
ExpiryMaterial

100 ㎍ , 500 ㎍, 10mg
Clear vial－20℃ (Avoid thawing)
Unopened vial 2 years at the storage condition above.
No animal derived ingredients are used in its
manufacture.

Version 03 (issued May 2016)

5. Quality statement
Higeta’s Animal-Free / GMP-compliant grade Recombinant
Human EGF( AOF/GMP hEGF) is for research and cell
culture applications, not intended for human in vivo
applications.
This product is manufactured and tested under a certified
ISO9001 quality system plus our own established GMPsystem. Our GMP system is based on Japanese veterinary
pharmaceuticals GMP and partially adopted ICH Q7.

6. Background
The recombinant human EGF, which is manufactured using
our facilities and quality management systems that comply
with GMP for veterinary pharmaceuticals, has been used inAustralia as an agent to harvest wool from sheep. Namely,
injection of EGF causes temporary halt of hair growthfollowed by weakeningof the juncture between
skin and hair. Thus thewool is pulled off fromsheep easily (as shownin the picture). Thistechnology attracts
attention as the next
generation wool
harvesting method.
AOF/GMP hEGF developed from this veterinary
pharmaceuticals. The product is further purified (polished)from veterinary grade.
AOF/GMP hEGF products are used in the various fields
such as cell culture for vaccine manufacturing or researchof regenerative medicine.

7. References
1) Yamagata, H. et al., Proc. Natl. Acad. Sci. 86, 3589-3593 (1989)
2) Carpenter,G., and Cohen,S., Annu.Rev.Biochem.,48, 193-216(1979)
3) Hirata, Y. et al., Endocrinol. Jpn. 33, 433-40 (1986)
4) Joyce, N.S., and Zhu, C.C., Cornea. 23, S8-S19(2004)
5) Tanaka, A. et al., J. Vet. Med. Sci. 67, 909-13 (2005)

8. Contact / Order
Higeta Shoyu Co., Ltd, R & D Department
1-5 HASAKI-SHINKOU, KAMISU-SHI, IBARAKI 314-0407,
JAPAN
TEL: +81-479-40-3355, FAX: +81-479-44-8882
E-mail: bio@higeta.co.jp

www.higeta.com